Abingworth LLP Verona Pharma PLC Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
A detailed history of Abingworth LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Abingworth LLP holds 2,457,500 shares of VRNA stock, worth $259 Million. This represents 21.3% of its overall portfolio holdings.
Number of Shares
2,457,500
Previous 2,457,500
-0.0%
Holding current value
$259 Million
Previous $25.1 Million
155.92%
% of portfolio
21.3%
Previous 8.58%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
322Shares Held
76.7MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$645 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$579 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$434 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$356 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$321 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.41B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...